BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shed $7.92 (66%) to $4.02 on Tuesday after its mesenchymal stem cell therapy NurOwn missed the primary endpoint in a...

DISEASE CATEGORY: Inflammation INDICATION: Eosinophilic esophagitis Inhibiting the extracellular serine protease KLK5 or its substrate PAR2 could treat eosinophilic esophagitis, a food antigen-driven inflammatory disease. Single-cell sequencing revealed aberrant KLK5 expression in multiple cell populations...

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies. Founded by targeted degradation pioneer Craig Crews in 2013,...

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious. Wednesday’s presentation of Phase I data of ARV-110 for metastatic castration-resistant prostate cancer...

Arvinas said it has started dosing metastatic castration-resistant prostate cancer patients in a Phase I trial of ARV-110, an oral androgen receptor-targeted PROTAC. Preliminary data are expected next half. Arvinas Inc. (NASDAQ:ARVN) said it believes...

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the...

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily oral Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2...

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2 trial...

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...